Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
← Back to archive
2022 SDI Disadvantage

AT - Food Innovation DA - MSDI 2022

AT - Food Innovation DA - MSDI 2022.docx

Download Word file
Indexed text preview
AFF ANSWERS
2AC---BioPharma UQ
BioPharma is already prepared to deal with a regulatory environment from the FTC and Congress – current labor and supply shortages coupled with geopolitical tensions created tensions in the sector
Glenn Hunzinger and Roel Van Den Akker, June 2022, (Glenn Hunzinger and Roel Van Den Akker, Glenn is a Partner, Pharmaceutical and Life Sciences Consulting Solutions Leader, PwC US, Roel is Partner, PwC US., June 2022, PwC, Pharmaceutical life sciences: Deals 2022 midyear outlook, https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html, 7-5-2022) SCade
All of the stars are aligned for there to be a flurry of deals activity across all areas of the sector despite the slow start to the year so far. Many large pharma players are flush with cash (particularly those that have COVID-19 treatments in their arsenal), biotech valuations have been normalizing after years of a boom market and the 2025 patent cliff is rapidly approaching, all making for a strong deal environment. Given the broader labor changes, supply shortages and constantly changing supply chain strategies and operations, the focus on quality can be challenging to sustain. Yet the downside can have massive impacts on businesses, including the potential inability to manufacture products. The long litany of macroeconomic and regulatory headwinds has CEOs looking for transactions that are easily integrated and will get cash off their balance sheet as inflationary pressures mount. Pharmaceutical & life sciences deals outlook Increased scrutiny from the US Federal Trade Commission (FTC) around larger deals could mean that 2022 will be a year of bolt-on transactions in the $5 to $15 billion range as pharma companies take multiple shots on goal in order to make up for revenues lost to generic competition in the remainder of the decade. However, don’t rule out the potential for larger deals ⁠— consolidation is good for the health ecosystem and drives broader efficiency. Expect to see big pharma picking up earlier stage companies to try and fill the pipeline gaps that are likely to start in 2024. While market conditions suggest bargain prices for biotech are possible, recent transactions indicate that pharma companies are still paying significantly above current trading prices (ranging from approximately 50 to 100% of current trading), but below the peak valuations of recent memory. In the first few months of the year, semi-annualized deal value was down 58% from the same period last year, with companies investing just $61.7 billion so far. Only 137 deals were announced during that time, compared to 204 in the year-prior period. Talk of drug pricing regulations continues in Washington as Congress bats around a pared down version of the Build Back Better plan. Expect some of that tension to ease in the fall if a new Congress takes on a different agenda. Other areas of the sector like medical devices face similar headwinds from regulators, and continue to deal with a greater impact from semiconductor shortages. Even though semi-annualized deal value in the medical device space is down 85% from the same period the prior year, expect these companies to remain focused on M&A as the subsector searches for alternative forms of revenue ⁠— particularly from new consumer-centric technologies. Macroeconomic headwinds and geopolitical tensions have created volatility in spending at CDMOs and CROs, limiting their willingness to deploy capital as the uncertainty persists.
The Pharma subsector isn’t doing any better – but their main profits are drugs
Glenn Hunzinger and Roel Van Den Akker, June 2022, (Glenn Hunzinger and Roel Van Den Akker, Glenn is a Partner, Pharmaceutical and Life Sciences Consulting Solutions Leader, PwC US, Roel is Partner, PwC US., June 2022, PwC, Pharmaceutical life sciences: Deals 2022 midyear outlook, https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html, 7-5-2022) SCade
Pharma
Deal activity in the pharma space is down by 30% on a semi-annualized basis. Yet, deal values have dropped about 50% in that time period, reflecting pharma’s appetite for smaller deals around a single asset or bolt-on deals, as the industry attempts to stay below the radar of regulators at the FTC. Like most other sectors, pharma continues to experience labor shortages, supply chain snags and higher input costs ⁠— particularly around packaging ⁠— due to inflationary pressures. In an effort to stay nimble in a rapidly changing environment, pharma companies are re-examining capital allocation strategies, as well as considering alternative options for their supply chains. Even as uncertainty persists, expect pharma to focus on inorganic growth ahead of some of the world’s largest drugs going off patent later this decade.
Biotech peaked and is coming down now – HARD
Glenn Hunzinger and Roel Van Den Akker, June 2022, (Glenn Hunzinger and Roel Van Den Akker, Glenn is a Partner, Pharmaceutical and Life Sciences Consulting Solutions Leader, PwC US, Roel is Partner, PwC US., June 2022, PwC, Pharmaceutical life sciences: Deals 2022 midyear outlook, https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html, 7-5-2022) SCade
Biotech
The XBI biotechnology index hit a peak in January 2021, outpacing the S&P 500, but has been on the decline since with more than 60 biotechs announcing layoffs in 2022 so far and several announcing they are closing their doors for good. There were 104 biotech IPOs in 2021 that raised nearly $15 billion in funds, while 2022 has seen only 14 IPOs raising less than $2 billion collectively. While biotech executives have been slow to accept lower valuations, Pfizer’s recently announced acquisition of Biohaven and GlaxoSmithKline’s announced deals with Sierra Oncology and Affinivax suggest more companies are willing to explore alternative means of financing as capital becomes harder to come by.
Biopharma is doing poorly now – Congress and rapidly changing regulatory environment – the aff is a drop in the bucket
Investors Business Daily, 22, (Investor'S Business Daily, 7-1-2022, Investor's Business Daily, Biotech Stocks To Watch: Track The Latest News On Pharmaceutical Stocks And Drug Companies, https://www.investors.com/news/technology/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead/, 7-5-2022) SCade
One minute Dow Jones industrial average component Merck (MRK) might be doing battle with fellow drugmaker Bristol Myers Squibb (BMY) over drugs that can ward off cancer. The next, biotech giants like Amgen (AMGN) and Sanofi (SNY) are tussling in court over the fate of cholesterol-busting drugs. Meanwhile, a company like Gilead Sciences (GILD) might be raked over the coals in Congress for charging $1,000 a day to treat hepatitis. It's a brave — and contentious — new world for pharmaceutical and biotechnology companies. It's a realm where science is trying to develop landmark medicines that cure cancer. Think Novocure (NVCR), hepatitis and other life-threatening illnesses. All the while it does a delicate dance with Wall Street and regulators — balancing public health issues with the demands of shareholders. Investors will find it tricky to navigate the sector, as companies can rise and fall at the drop of a hat.
The merge of biotech and big pharma hurts innovation
Tracy Staton, Aug 30, 2016 10, Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for 8 years. Before that, she served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont and can be reached at tracy@fiercemarkets.com, or find her on LinkedIn."It's official: Pharma mergers hurt innovation, and not only for the dealmakers", Fierce Pharma, https://www.fiercepharma.com/pharma/it-s-official-pharma-mergers-hurt-innovation-and-not-only-for-dealmakers, 7-4-2022, //ms
Pharma mergers might boost short-term profits. But long-term value? Think again, because everyone knows that big mergers hurt innovation. That’s the claim, at least, repeated by critics every time a major pharma combo hits the news. Problem is, those complaints tend to be based on anecdotal evidence, from scientists who’ve seen their work hit the slough of despond as one big R&D operation integrated with another. But now, the Harvard Business Review has some empirical evidence. Two researchers from the Institute for Competition Economics in Germany set out to address drug mergers from an antitrust perspective. All well and good for competition watchdogs to look at overlaps in companies’ marketed products and pipelines, they figured. What about the drugs that might have The researchers analyzed 65 pharma deals, comparing the participating companies before and after they combined. They also analyzed companies that were developing drugs in similar therapeutic areas, but hadn’t merged. “Our results very clearly show that R&D and patenting within the merged entity decline substantially after a merger, compared to the same activity in both companies beforehand,” the authors, Justus Haucap and Joel Stiebale, wrote in the HBR. That’s to be expected, the authors posit, because merger-minded companies often target rivals with similar pipeline assets, to gain strength in particular drug markets. But here’s what else the authors found: “On average, patenting and R&D expenditures of non-merging competitors also fell--by more than 20%--within four years after a merger. Therefore, pharmaceutical mergers seem to substantially reduce innovation activities in the relevant market as a whole." Haucap and Stiebale’s paper includes patent counts and R&D spending numbers, and they conclude that “innovation output” by the merged company decreases, on average, by more than 30%. Among the merged company’s competitors, output declined by 7%, on average, they found. The men’s research “is the first to show that there are follow-on effects across the industry,” wrote Derek Lowe at In The Pipeline, which has sliced and diced pharma M&A for years. “Inside the merged companies, there’s a great deal of disruption, as many readers here can testify,” Lowe wrote. “But across the industry as a whole, things get less competitive the fewer players there are and the fewer the approaches being tried.” As for the business effects? Profitability increased post-merger, for the merged companies and for their competitors, too. For the merged company, the profits may depend on cost cuts; in integrating, the post-merger company “decreases its scale” compared to the two merger partners, pre-acquisition. For “non-merging rivals,” profits tended to grow on increased sales. “What we have, then, is probably a perverse incentive--companies can improve their numbers by doing mergers and acquisitions, but that very activity hurts their long-term prospects and those of the entire industry,” Lowe observes. McKinsey & Co. analysts emphasized the “shareholder value” effects of megamergers in a 2014 study, and they found that, reductively speaking, the deals worked. Lowe picked apart that research, as did ex-Pfizer R&D chief John LaMattina, who wrote up his own rebuttal in Forbes, enumerating the many ways repeated megamergers sap the life out of research, as focus and energy go into logistical decisions, layoff worries, and the like--and away from science.\
Trends prove that the chemical industry’s fate is sealed
Ge Digital, 2021, (Ge Digital, 2021, General Electric, The Future of the Chemical Industry, https://www.ge.com/digital/blog/future-chemical-industry, 6-25-2021) SCade
Four chemical industry trends to watch There are four broad trends currently defining the chemical industry, each affecting a different element of business, from operations through production and compliance.
Mergers and acquisitions: The last couple of years saw notable consolidation in the form of multiple mergers and acquisitions. A result of slow overall industry growth and a desire to consolidate resources and capabilities in the areas with the most promising growth, M&A is also being driven by growing pressure to gather the resources needed for digital transformation. Mega mergers are radically altering the top of the industry­­–a fact that has not escaped the attention of farmers, legislators, and regulatory bodies.
A new regulatory environment: Governments and regulatory bodies around the world are overhauling chemical regulations for the first time in decades. Both environmental and industry groups note that these changes could signal a kind of détente between the chemical industry and its watchdogs over the next few years. In other parts of the world, however, the relationship between the industry, activist groups, and regulatory bodies remains more acrimonious.
Investment: After decades of taking a back seat to emerging markets, North America saw a significant wave of investments in new multi-billion-dollar production facilities from a number of chemical manufacturers. Factors involved in this growth include the considerable size and strength of the regional market, and favorable political and regulatory environments in American states with significant chemical production segments.
Digital transformation: Rising demand and growing competition have increased the pressure on all chemical manufacturers to adopt advanced technologies and transform their operations and structures. Improved efficiencies, safety, and reliability can be realized through implementation of advanced technology–all of which can reduce costs for the manufacturer. These transformations are also enabling new business models that could bring chemical manufacturers closer to their suppliers, their direct customers, and even their end customers.
2AC---BioPharma Link D
still can use CRISPR for other editing and advances.
Gregory E. Kaebnick is a research scholar at The Hastings Center and the editor of theHastings Center Report. A Moratorium on Gene Editing? March 27 2015 https://www.thehastingscenter.org/a-moratorium-on-gene-editing/
CRISPR/Cas9 can be turned to many other uses than editing the human germline, however. One of the most extraordinary is the possibility of using it in “gene drives” that could be make genetic modifications to sexually reproducing populations of microorganisms, animals, or plants. Sexually reproducing organisms have two sets of gene—one from each parent. A gene drive is a set of genes that, if it is inserted into one set, will get itself copied to the appropriate location on the other set, replacing any competing genes and also ensuring that all of the organism’s offspring receive the drive. Within those offspring, the drive will again replace any competing genes, ensuring that all of the next generation receives the gene. If a species reproduces rapidly, it might be possible to quickly alter the whole species. Mosquitoes could be altered so that they can no longer transmit malaria or dengue, for example.
no link- ban doesn’t apply to research uses or somatic editing.
Lander, et.al. 2019 Eric S. Lander , Françoise Baylis , Feng Zhang , Emmanuelle Charpentier , Paul Berg , Catherine Bourgain , Bärbel Friedrich , J. Keith Joung , Jinsong Li , David Liu , Luigi Naldini , Jing-Bao Nie , Renzong Qiu , Bettina Schoene-Seifert , Feng Shao , Sharon Terry , Wensheng Wei & Ernst-Ludwig Winnacker 13 March 2019 Adopt a moratorium on heritable genome editing https://www.nature.com/articles/d41586-019-00726-5
To be clear, our proposed moratorium does not apply to germline editing for research uses, provided that these studies do not involve the transfer of an embryo to a person’s uterus. It also does not apply to genome editing in human somatic (non-reproductive) cells to treat diseases, for which patients can provide informed consent and the DNA modifications are not heritable.
2AC---BioPharma IL Defense
BioPharma bad – high profits are a result of price gouging drugs and tax credits. Innovation doesn’t happen in big pharma now.
Abbey Meller and Hauwa Ahmed, 8-30-2019, Abbey Meller is an organizing associate for Democracy and Government at the Center for American Progress. Hauwa Ahmed is a research assistant for Democracy and Government at the Center. "How Big Pharma Reaps Profits While Hurting Everyday Americans", Center for American Progress, https://www.americanprogress.org/article/big-pharma-reaps-profits-hurting-everyday-americans/, 7-3-2022, //ms
It’s no secret that the Trump administration has fostered a culture of corruption in which special interests and big donors advance their interests at the expense of everyday people. Perhaps no policy area exemplifies this corruption more than the issue of drug pricing. President Trump has long promised to stand up to the pharmaceutical industry and lower prescription drug prices, but he has avoided taking serious action to drive down prices while at the same time filling top spots in his administration with industry insiders. This administration’s culture of corruption, which continues a decadeslong practice of political pandering to the pharmaceutical industry, carries a real cost; Americans spent $535 billion1 on prescription drugs in 2018, an increase of 50 percent since 2010. These price increases far surpass inflation, with Big Pharma increasing prices on its most-prescribed medications by anywhere from 40 percent to 71 percent from 2011 to 2015.2 Moreover, pharmaceutical companies receive substantial U.S. government assistance in the form of publicly funded basic research and tax breaks, yet they continue to charge exorbitant prices for medications. But the issue goes beyond cost. In America, more than 1 million individuals suffer from Type 1 diabetes3, a condition where the body cannot make insulin, which is essential for getting glucose (also known as blood sugar) into cells from the bloodstream. Without insulin, glucose accumulates in the bloodstream4, causing dangerously high blood sugar levels. Among all Americans suffering from diabetes, at least 1 in 45 have said that they engaged in insulin rationing—a tactic of using less insulin than is needed in order to make the doses last longer—as a direct result of the skyrocketing price of the drug. A vial of insulin, which is the only life-sustaining option for Type 1 diabetics, retails at around $300.6 A 2018 study commissioned by the Congressional Diabetes Caucus found that the price of insulin has doubled since 20127; in the 10 years prior, the price of insulin nearly tripled. Despite the dangers of insulin rationing, which can lead to diabetic ketoacidosis, a fatal condition, many Americans have no other choice. That was the case for Antroinette8, whose daughter was rationing insulin due to the high cost and died at the age of 22 as a result. Insulin facts Access to insulin for patients with Type 1 diabetes is a matter of life or death.9 While insulin has existed since the1920s10, the price since then has skyrocketed, especially in recent years. Prices for insulin increased by 197 percent between 2002 and 2013, from $4.34 per milliliter to $12.92 per milliliter.11 There are three insulin manufacturers serving the United States: Eli Lilly and Co., Novo Nordisk A/S, and Sanofi SA. Eli Lillyannounced12 in March 2019 that it would begin selling a generic version of its Humalog insulin at half the price. The medication, known as lispro, will cost $137.35 per vial. To compare pricing, a 2018 study13 estimated that the cost of making a year’s worth of insulin for one patient ranges from $78 to $133. Ahead of its hearing on drug pricing in February 2019, the U.S. Senate Committee on Finance sent aletter14 to Eli Lilly asking why insulin is priced so astonishingly high. A vial of NovoLog, one type of insulin, costs15 anywhere from $14 to $300 in the United States but only $48 in Singapore, $1

Preview shortened. Download the file for the full document.